DRAFT AGENDA

FIFRA SCIENTIFIC ADVISORY PANEL (SAP)

	OPEN MEETING

	

February 27 – 28, 2007

FIFRA SAP WEB SITE http://www.epa.gov/scipoly/sap/

OPP Docket Telephone: (703) 305-5805

Docket Number: EPA-HQ-OPP-2006-0987

U.S. Environmental Protection Agency

Conference Center - Lobby Level

One Potomac Yard (South Bldg.)

2777 S. Crystal Drive, Arlington,VA 22202

Review of the Status of the In Utero Through Lactational Assay in the
Endocrine Disruptor Screening Program

Tuesday, February 27, 2007

8:30 A.M.	Introduction and Identification of Panel Members - 

		Steven G. Heeringa, Ph.D. (FIFRA SAP Chair)  

8:40 A.M.	Administrative Procedures by Designated Federal Official - 

		Bill Wooge, Office of Science Coordination and Policy, EPA

8:45 A.M.	Welcome and Opening Remarks – Clifford Gabriel, Ph.D.
Director, Office of Science Coordination and Policy, EPA

8:50 A.M.	Opening Remarks – Elaine Francis, Ph.D. Office of Research
and Development, EPA

8:55 A.M.	Introduction of Team – Linda Phillips, Ph.D., Acting
Division Director, Exposure Assessment Coordination and Policy Division,
OSCP, EPA

9:00 A.M.	Overview of the Endocrine Disruptor Screening Program/
Introduction to the In Utero Through Lactation Assay – Gary Timm, 
Office of Science Coordination and Policy, EPA

10:00 A.M.	BREAK

10:15 A.M.	The Development of the In Utero/Lactational Assay for the
U.S. EPA EDSP – Rochelle Tyl, Ph.D., DABT, RTI International

11:45 A.M.	LUNCH

1:00 P.M.	In Utero Through Lactational Assay from a Research Perspective
- Earl Gray, Ph.D., Office of Research and Development, EPA

1:30 P.M.	Life-Stages Developmental and Reproductive Test Enhanced to
Detect Endocrine Effects in the EDSP Tier 2 – Ralph Cooper, Ph.D.,
Office of Research and Development, EPA

2:00 P.M.	Overview and Specific Charges to the SAP – Don Bergfelt,
Ph.D., Office of Science Coordination and Policy, EPA

2:30 P.M.	BREAK

2:45 P.M.	Public Comments



3:45 P.M.	Specific Charge 1:  Considering the current biology and
logistics, time, cost and other resources involved in conducting an in
utero through lactational screening assay, please comment on the need,
strengths, weaknesses and practicality of developing and validating the
bioassay as an EDSP Tier-1 screen.

5:00 P.M. 	Adjournment

Draft AGENDA

FIFRA SCIENTIFIC ADVISORY PANEL (SAP)

	OPEN MEETING

	

February 27 – 28, 2007

FIFRA SAP WEB SITE http://www.epa.gov/scipoly/sap/

OPP Docket Telephone: (703) 305-5805

Docket Number: EPA-HQ-OPP-2006-0987

U.S. Environmental Protection Agency

Conference Center - Lobby Level

One Potomac Yard (South Bldg.)

2777 S. Crystal Drive, Arlington,VA 22202

Review of the Status of the In Utero Through Lactational Assay in the
Endocrine Disruptor Screening Program

Wednesday, February 27, 2007

8:30 A.M.	Introduction and Identification of Panel Members - 

		Steven G. Heeringa, Ph.D. (FIFRA SAP Chair)  

8:40 A.M.	Administrative Procedures by Designated Federal Official - 

		Bill Wooge, Office of Science Coordination and Policy, EPA

8:45 A.M.	Specific Charge 2: Please comment on the basis for supporting
continued development and validation of an in utero through lactational
screening assay using Protocol C in the EDSP Tier-1 battery.

9:45 A.M.	Specific Charge 3: Please comment on the basis for supporting
development and validation of a revised Protocol C or alternative
Protocols A or B or some other protocol for an in utero through
lactational screening assay in the EDSP Tier-1 battery.  What are the
strengths and weaknesses of a revised Protocol C or alternative
protocols and would this revised in utero through lactational screening
assay be considered an alternative assay, if so, replacing what assays,
or an additional assay in the EDSP Tier-1 battery?

10:45 A.M.	BREAK

11:00 A.M.	Specific Charge 4: Please comment on the basis for supporting
suspension of the present course for development and validation of the
in utero through lactational assay as an EPA screening assay in the
EDSP.  What research would be useful in developing an in utero through
lactational assay that would support reconsideration of the bioassay as
a screen in the Tier-1 battery?

12:00 P.M.	LUNCH

1:15 P.M.	Continuation of Questions to the Panel (as needed)

2:30 P.M.	Adjournment

Please be advised that agenda times are approximate; when the discussion
for one topic is completed, discussions for the next topic will begin. 
For further information, please contact the Designated Federal Official
for this meeting, Bill Wooge, via telephone:  (202) 564-8794; fax: 
(202) 564-8382; or email: wooge.william@epa.gov

